Big Pharma has hijacked “trade” agreements like the North American Free Trade Agreement (NAFTA) to expand their monopoly power and keep medicine prices high. The renegotiated NAFTA deal that Trump signed at the end of 2018 would have required governments to guarantee 10 years of data exclusivity for biologic drugs. This would have locked the United States into our bad policies that keep these medicines, including critical cancer treatments, outrageously expensive and export our failed system to Mexico and Canada. Before it was signed into law, congressional Democrats, unions and civil society groups forced Trump to reopen the 2018 NAFTA deal to remove Big Pharma giveaways and strengthen labor and environmental terms.
NAFTA 2.0's Special Giveaways to Big Pharma
Download our latest resource highlighting NAFTA 2.0's special giveaways to Big Pharma.
Public Citizen's NAFTA 2.0 Text Analysis
The revised NAFTA deal that Donald Trump signed would lock in high U.S. medicine prices. Read our analysis.